DK3265482T3 - Integrin-targeterende protein og anvendelsesmåder deraf - Google Patents
Integrin-targeterende protein og anvendelsesmåder derafInfo
- Publication number
- DK3265482T3 DK3265482T3 DK16762256.2T DK16762256T DK3265482T3 DK 3265482 T3 DK3265482 T3 DK 3265482T3 DK 16762256 T DK16762256 T DK 16762256T DK 3265482 T3 DK3265482 T3 DK 3265482T3
- Authority
- DK
- Denmark
- Prior art keywords
- integrin
- methods
- targeting protein
- targeting
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129499P | 2015-03-06 | 2015-03-06 | |
| PCT/US2016/021037 WO2016144815A1 (en) | 2015-03-06 | 2016-03-04 | Integrin-targeting protein and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3265482T3 true DK3265482T3 (da) | 2026-01-12 |
Family
ID=56880437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16762256.2T DK3265482T3 (da) | 2015-03-06 | 2016-03-04 | Integrin-targeterende protein og anvendelsesmåder deraf |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180044403A1 (da) |
| EP (2) | EP4706760A2 (da) |
| JP (4) | JP6789961B2 (da) |
| CN (1) | CN107709354B (da) |
| AU (3) | AU2016230009A1 (da) |
| CA (1) | CA2978597A1 (da) |
| DK (1) | DK3265482T3 (da) |
| ES (1) | ES3058649T3 (da) |
| FI (1) | FI3265482T3 (da) |
| WO (1) | WO2016144815A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118028214B (zh) * | 2022-12-30 | 2025-05-16 | 珠海市藤栢医药有限公司 | 过表达整合素的人脐静脉内皮细胞及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA175122A (en) | 1916-11-27 | 1917-02-13 | Segmond Schwerin | Ornamenting surface |
| CA2454618C (en) * | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| EP1587912A2 (en) * | 2003-01-30 | 2005-10-26 | The General Hospital Corporation | Methods of identifying and designing cell surface receptor inhibitors |
| JP2008518022A (ja) * | 2004-10-27 | 2008-05-29 | メディミューン,インコーポレーテッド | 線維症関連疾患を治療するためのEphA2およびエフリンA1モジュレーター |
| US8227419B2 (en) * | 2006-02-03 | 2012-07-24 | Crc For Asthma And Airways Ltd. | Method of treating conditions associated with airway tissue remodeling |
| WO2008045252A2 (en) * | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US9175063B2 (en) * | 2010-07-13 | 2015-11-03 | Georgia State University Research Foundation | Anti-angiogenic agent and methods of using such agent |
| GB201013573D0 (en) * | 2010-08-12 | 2010-09-29 | Ucl Business Plc | Treatment |
| WO2021009471A1 (en) | 2019-07-18 | 2021-01-21 | Total E&P Uk Limited | A method of optimizing production from a hydrocarbon reservoir |
-
2016
- 2016-03-04 AU AU2016230009A patent/AU2016230009A1/en not_active Abandoned
- 2016-03-04 DK DK16762256.2T patent/DK3265482T3/da active
- 2016-03-04 CA CA2978597A patent/CA2978597A1/en active Pending
- 2016-03-04 CN CN201680023904.3A patent/CN107709354B/zh active Active
- 2016-03-04 EP EP25213156.0A patent/EP4706760A2/en active Pending
- 2016-03-04 US US15/555,442 patent/US20180044403A1/en active Pending
- 2016-03-04 JP JP2017546808A patent/JP6789961B2/ja active Active
- 2016-03-04 ES ES16762256T patent/ES3058649T3/es active Active
- 2016-03-04 FI FIEP16762256.2T patent/FI3265482T3/fi active
- 2016-03-04 WO PCT/US2016/021037 patent/WO2016144815A1/en not_active Ceased
- 2016-03-04 EP EP16762256.2A patent/EP3265482B1/en active Active
-
2020
- 2020-11-04 JP JP2020184439A patent/JP2021046402A/ja active Pending
- 2020-11-30 AU AU2020280987A patent/AU2020280987A1/en not_active Abandoned
-
2022
- 2022-12-28 JP JP2022211437A patent/JP2023052154A/ja active Pending
-
2024
- 2024-06-11 AU AU2024203940A patent/AU2024203940A1/en active Pending
-
2025
- 2025-01-31 JP JP2025015402A patent/JP2025078632A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017135220A (ru) | 2019-04-05 |
| EP3265482B1 (en) | 2025-11-05 |
| US20180044403A1 (en) | 2018-02-15 |
| JP2018510861A (ja) | 2018-04-19 |
| JP2023052154A (ja) | 2023-04-11 |
| JP2021046402A (ja) | 2021-03-25 |
| FI3265482T3 (fi) | 2026-01-16 |
| WO2016144815A1 (en) | 2016-09-15 |
| CN107709354B (zh) | 2022-01-04 |
| EP3265482A1 (en) | 2018-01-10 |
| EP4706760A2 (en) | 2026-03-11 |
| AU2020280987A1 (en) | 2021-01-07 |
| AU2024203940A1 (en) | 2024-07-04 |
| CN107709354A (zh) | 2018-02-16 |
| JP6789961B2 (ja) | 2020-11-25 |
| JP2025078632A (ja) | 2025-05-20 |
| EP3265482A4 (en) | 2018-11-21 |
| RU2017135220A3 (da) | 2019-07-24 |
| CA2978597A1 (en) | 2016-09-15 |
| AU2016230009A1 (en) | 2017-10-12 |
| ES3058649T3 (en) | 2026-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| ZA202004919B (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| IL282372A (en) | Haploid induction compositions and methods for use therefor | |
| ZA202003695B (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| IL259747A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| IL255269A (en) | Compositions of obeticholic acid and methods of use | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3474996T3 (da) | Tågeapparat og anvendelsesmåde | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3303386T3 (da) | Anti-Tau-antistoffer og fremgangsmåder til anvendlelse | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3356404T3 (da) | Anti-pd1-antistoffer og fremgangsmåder til anvendelse | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
| DK3514151T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| IL254670A0 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| DK3551209T3 (da) | Insulin-fc-fusioner og fremgangsmåder til anvendelse | |
| PL3565828T3 (pl) | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania | |
| PL3371206T3 (pl) | Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka | |
| HUE054093T2 (hu) | Anti-HtrA1 antitestek és azok alkalmazási eljárásai |